The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer

Schneider, Bryan P.; Radovich, Milan; Miller, Kathy D.

doi:10.1158/1078-0432.ccr-08-2576

Cited by 77 publications

(50 citation statements)

References 57 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reviewed that the OVCA429 ovarian cancer cell line employed in this study expresses both EGFR and ErbB2. 38 In our study, EXD significantly inhibited ErbB2 expression in the xenograft model ( Figure 6C) but not in the cancer cell model ( Figure 4A and B). Besides, EXD significantly inhibited VEGF expression in both models and lowered the migrating and invasive abilities of OVCA429 cells, indicating that EXD played an important role in ovarian cancer metastasis and invasion mainly by targeting VEGF (Figures 4D and 6C).…”

Section: Discussionmentioning

confidence: 45%

An In Vitro and In Vivo Investigation of the Antimetastatic Effects of a Chinese Medicinal Decoction, Erxian Decoction, on Human Ovarian Cancer Models

et al. 2012

View full text Add to dashboard Cite

Objectives. Erxian Decoction (EXD) is a well-documented Chinese medicinal formulation, which has been clinically applied for years for relieving menopausal syndromes by modulating hormonal levels indicating that EXD might also be effective in treating hormone-related tumors. This study aimed to differentially investigate the efficacy of EXD and its antimetastatic property on human ovarian cancer cells, OVCA429. Methods. The efficacy and cell cycle progression of EXD on OVCA429 cells was determined by MTT assay and flow cytometry, respectively. The modulated expression of metastatic markers by EXD in OVCA429 cells and xenografts was evaluated at transcriptional and translational levels by Western blotting and real-time polymerase chain reaction, respectively. The migrating and invasive ability of the cancer cells were determined by wound healing and invasive assays. Results. The IC 50 value of EXD on OVCA429 cells was determined after 24 hours incubation with EXD at 1 mg/mL. EXD (1.5 mg/mL) mediated S-phase cell cycle arrest and apoptotic cell death at 24 hours posttreatment. EXD repressed the expression of several metastatic mediators, including EGFR, ErbB2, MMP2, MMP7, MMP9, and VEGF in OVCA429 cells and xenografts at transcriptional and/or translational levels. Furthermore, EXD functionally demonstrated significant inhibition of migrating and invasive ability of OVCA429 cells. EXD suppressed tumor size in xenografts without any adverse effects on body weight. Conclusions. This is the first study that illustrates the antimetastatic property of EXD on human ovarian cancer models. This decoction merits serious consideration for further delineation of its multiple pharmacological effects, especially on hormone-related cancers, and these would be valuable for future clinical applications of EXD as an alternative regime for cancers.

show abstract

Section: Discussionmentioning

confidence: 45%

An In Vitro and In Vivo Investigation of the Antimetastatic Effects of a Chinese Medicinal Decoction, Erxian Decoction, on Human Ovarian Cancer Models

et al. 2012

View full text Add to dashboard Cite

show abstract

“…However, the same authors considered the VGPs analysis performed on tumor DNA and the lack of available peripheral blood samples as limitations of the study. According to Schneider et al, clinically meaningful polymorphisms of angiogenesis genes should be found, in fact, in normal germline DNA because tumor angiogenesis is mediated by "normal" endothelial, hematopoietic, and stromal cells [22].…”

Section: Discussionmentioning

confidence: 99%

“…The region upstream of the start codon (i.e., the promoter/ 5'UTR) has been shown to contain all the major regulatory VEGF gene sites [22]. In particular, the VEGF −2578 CC and −1154 GG genotypes have been associated with a higher VEGF expression [23].…”

Section: Molecular Analysis Of Vegf Polymorphismmentioning

confidence: 99%

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

Formica

Palmirotta

Monte³

et al. 2010

Int J Colorectal Dis

View full text Add to dashboard Cite

show abstract

“…60,61 However, in a retrospective analysis of ECOG2100, the presence of a germline single nucleotide polymorphism in the 5-prime untranslated region of VEGF-A, −2578AA and −1154AA showed a correlation with overall improved survival, as did the presence of greater than grade 2 hypertension. 62 Whether the differences in treatment outcomes are large enough to warrant stratification of patients according to these criteria, however, will need to be clarified in further studies.…”

Section: Discussionmentioning

confidence: 99%

Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review

Pories

Wulf

2010

BCTT

View full text Add to dashboard Cite

Angiogenesis inhibitors may provide a new approach to the treatment of metastatic breast cancer. Bevacizumab is a monoclonal antibody against pathologic angiogenesis. A pivotal study (ECOG 2100) showed that bevacizumab in combination with paclitaxel increased progression-free survival for patients with metastatic breast cancer by 6 months. Subsequently, several clinical trials have shown that the combination of bevacizumab with a taxane can improve disease-free survival but does not prolong overall survival. While generally well tolerated, bevacizumab is potentially toxic for some patients who develop hypertension, proteinuria, bleeding, impaired wound healing, bowel perforation or thromboembolic events. Here, we review the current evidence for the use of bevacizumab in breast cancer and ongoing studies that address the questions of how to optimize regimens and schedules for the use of anti-angiogenic agents and the identification of those patients who would benefit the most from treatment with regimens that include antiangiogenic therapy.

show abstract

The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer

Abstract: Angiogenesis is a hallmark of tumor pathogenesis. Vascular endothelial growth factor

Cited by 77 publications

References 57 publications

An In Vitro and In Vivo Investigation of the Antimetastatic Effects of a Chinese Medicinal Decoction, Erxian Decoction, on Human Ovarian Cancer Models

An In Vitro and In Vivo Investigation of the Antimetastatic Effects of a Chinese Medicinal Decoction, Erxian Decoction, on Human Ovarian Cancer Models

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review

Contact Info

Product

Resources

About